Zydus Cadila has received the final approval from the USFDA to market Ranitidine Hcl injection 25 mg/ml. Used in the treatment of peptic ulcers, gastritis and gastroesophageal reflux disease (GERD), Ranitidine Hcl falls in the anti-secretory segment.
The estimated sales in 2012 as per IMS for Ranitidine Hcl injection was $5.4 million. The group now has 76 approvals and has so far filed 172 ANDAs since the commencement of the filing process in FY 2003-04.
Flagship company of Zydus Cadila Group, it focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1462.50 |
Dr. Reddys Lab | 5784.50 |
Cipla | 1451.25 |
Zydus Lifesciences | 1001.15 |
Lupin | 1587.90 |
View more.. |